Search research articles
Contact Us
Filters
Showing results (211-220 of 268) with videos related to
Page
of 27
Sort By:
BMC Genomics
|
December 19, 2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
Karen A Ryall, Jihye Kim, Peter J Klauck, et al.
Plos One
|
November 2, 2017
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
Aaron J Scott, Eun-Kee Song, Stacey Bagby, et al.
Nature Computational Science
|
March 4, 2024
Population-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data
Daniel Osorio, Anna Capasso, S Gail Eckhardt, et al.
Molecular Cancer Therapeutics
|
March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
John J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Developmental Biology
|
July 12, 2022
Peripheral nerve development in zebrafish requires muscle patterning by tcf15/paraxis
Lauren E Limbach, Rocky L Penick, Rudy S Casseday, et al.
Anti-Cancer Drugs
|
July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Anna Capasso, Todd M Pitts, Peter J Klauck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models
Jennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2012
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib
John J Arcaroli, Kevin S Quackenbush, Rebecca W Powell, et al.
Investigational New Drugs
|
December 31, 2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R Kessler, S Gail Eckhardt, Todd M Pitts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2011
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models
M Pia Morelli, John J Tentler, Gillian N Kulikowski, et al.
Page
of 27
Search research articles
Search
Showing results (211-220 of 268) with videos related to
Sort By:
Page
of 27
BMC Genomics
|
December 19, 2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
Karen A Ryall, Jihye Kim, Peter J Klauck, et al.
Plos One
|
November 2, 2017
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
Aaron J Scott, Eun-Kee Song, Stacey Bagby, et al.
Nature Computational Science
|
March 4, 2024
Population-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data
Daniel Osorio, Anna Capasso, S Gail Eckhardt, et al.
Molecular Cancer Therapeutics
|
March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
John J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Developmental Biology
|
July 12, 2022
Peripheral nerve development in zebrafish requires muscle patterning by tcf15/paraxis
Lauren E Limbach, Rocky L Penick, Rudy S Casseday, et al.
Anti-Cancer Drugs
|
July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Anna Capasso, Todd M Pitts, Peter J Klauck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models
Jennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2012
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib
John J Arcaroli, Kevin S Quackenbush, Rebecca W Powell, et al.
Investigational New Drugs
|
December 31, 2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R Kessler, S Gail Eckhardt, Todd M Pitts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2011
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models
M Pia Morelli, John J Tentler, Gillian N Kulikowski, et al.
Page
of 27